| Document |
Document Title |
|
WO/2022/206090A1 |
A pentoxifylline injection. A preparation method for the pentoxifylline injection comprises: adding an osmotic pressure regulator of a prescribed amount into injection water that accounts for 40-60% of a total preparation volume and stir...
|
|
WO/2022/207924A1 |
The present invention relates to compounds of formula (I). The compounds of the formula (I) are e.g. (S)-1-(5-((pyridin-3-yl)thio) pyrazin-2-yl)-4lH,6'H-spiro[piperidine-4,5'-pyrrolo[l,2-b]py
razol]-4l- amine derivatives and similar comp...
|
|
WO/2022/206986A1 |
Provided are gene therapy technologies, including specifically designed and tested guide RNA sequences for improved base editors, useful for increasing the expression of the gamma-globin gene. The guide RNA sequences may target the BCL11...
|
|
WO/2022/212645A1 |
Provided herein are methods for reducing or preventing surgery-associated hemolysis in subjects who have cold agglutinin disease (CAD) (e.g., been diagnosed with CAD or have had at least one symptom of CAD).
|
|
WO/2022/199552A1 |
Disclosed are an alpha-globin overexpression vector and an application thereof. The alpha-globin overexpression vector sequentially comprises: (1) a locus control region, an alpha-globin promoter, an HBA2 gene and a HBA2 gene 3'sequence ...
|
|
WO/2022/198361A1 |
Disclosed is a novel crystal form of dabigatran etexilate ethyl ester hydrochloride, the X-ray powder diffraction pattern thereof having diffraction peaks at 2θ ± 0.2°, and 2θ is at least selected from any one of 5.42 ± 0.2°, 9.08 ...
|
|
WO/2022/200580A1 |
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof.The co...
|
|
WO/2022/196816A1 |
Provided are a colicin-fighting monoclonal antibody molecule or a derivative thereof, and a pharmaceutical composition containing the same, for ameliorating acute lung injury and acute worsening of pulmonary fibrosis. The pharmaceutica...
|
|
WO/2022/197761A1 |
The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit f...
|
|
WO/2022/195532A1 |
Present invention relates to development of compound of formula (Ia) for treatment of sickle cell anaemia. Invention also relates to the pharmaceutical composition comprising compound of formula (Ia) or its pharmaceutically acceptable sa...
|
|
WO/2022/195355A1 |
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the...
|
|
WO/2022/195454A1 |
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the...
|
|
WO/2022/191330A1 |
Provided is a hemostatic material which can be safely used for more people, and is inexpensive and highly effective. Provided is a hemostatic material for preventing bleeding, which contains a cationized polysaccharide represented by for...
|
|
WO/2022/189279A1 |
The present invention relates to crystalline forms of (4S)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(t
rifluoromethyl)-32H-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazo
la-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide which are...
|
|
WO/2022/192730A1 |
The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing...
|
|
WO/2022/192731A1 |
The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing...
|
|
WO/2022/188877A1 |
The present invention relates to the technical field of medicines. Disclosed are a synthetic peptide and an application thereof. The chemical formula of the synthetic peptide is (Gly)x-(beta-Ala-L-His)y-(Gly)z, (Gly)x-(beta-Ala-L-1-Methy...
|
|
WO/2022/184005A1 |
Provided herein are thiosuccinyl-crosslinked hemoglobin conjugates useful as blood replacement agents and therapeutic proteins, pharmaceutical compositions comprising the same and the methods of use and preparation thereof.
|
|
WO/2022/183908A1 |
An industrial method for continuously extracting a high-content marigold flavonoid and a marigold flavonoid product obtained thereby. The method comprises the following steps: 1) granulating a marigold flower raw material, a ring mold co...
|
|
WO/2022/186331A1 |
A problem addressed by the present invention is to provide a formulation of an antibody or an antibody derivative capable of preventing or treating acquired von Willebrand syndrome (AVWS) that develops in association with diseases that r...
|
|
WO/2022/185160A1 |
The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using su...
|
|
WO/2022/186349A1 |
ADM and/or HHEX-highly expressing fibroblasts have been found as cells having lymphangiogenesis ability, and a means for treating fibrosis using a pharmaceutical composition containing said cells, a means for ameliorating a state in whic...
|
|
WO/2022/186170A1 |
Provided is a composition that is for preventing or treating cerebrovascular accident in a subject, and that contains a peptidylarginine deiminase 4 activator.
|
|
WO/2022/184176A1 |
Disclosed are a pharmaceutical composition containing ethanol and a use thereof. The pharmaceutical composition can be used in vivo for animals, and is prepared from the following raw material: ethanol having a concentration no lower tha...
|
|
WO/2022/185742A1 |
A prophylactic or therapeutic composition for disseminated intravascular coagulation syndrome, the composition comprising, as an active ingredient, at least one selected from adenosine A2a receptor antagonists and dopamine D2-like recept...
|
|
WO/2022/184159A1 |
Provided in the present invention are a crystal form of a quinolinone compound, the use thereof, a pharmaceutical composition containing same, and the use of the crystal form or the pharmaceutical composition in the preparation of a drug...
|
|
WO/2022/182523A1 |
Various aspects of this patent document relate to bioactive compositions comprising anions that are converted into hydrophobic bioactive molecules either ex vivo prior to administration to a subject or in situ subsequent to administratio...
|
|
WO/2022/180911A1 |
Provided is a cell preparation capable of treating hemophagocytic syndrome. The present invention is a cell preparation for use in the treatment of hemophagocytic syndrome, wherein the cell preparation includes umbilical cord-derived c...
|
|
WO/2022/179636A1 |
The present invention relates to crystal forms I, II, III, IV, V, VI, VII, VIII, and IX of an FXR receptor agonist 2-((1S,4S,5R)-5-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxaz
ol-4-yl)methoxy)-2-azabicyclo[2.2.1]heptane-2-yl)benzo[d]thi
...
|
|
WO/2022/181505A1 |
The present invention addresses the issue of providing: an albumin that is bound to a water-soluble polymer that has high biocompatibility and can be easily prepared (synthesized); and an artificial plasma expander and a resuscitation fl...
|
|
WO/2022/174334A1 |
The present disclosure provides a duplex or single-stranded siRNA molecule against plasminogen, the siRNA molecule containing modified or unmodified nucleotides and wherein at least one strand of the duplex or the single-stranded siRNA h...
|
|
WO/2022/178191A1 |
Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effe...
|
|
WO/2022/177267A1 |
The present invention relates to a compound for suppressing nonsense-mediated mRNA decay (hereinafter referred to as "NMD") and a pharmaceutically acceptable salt thereof. The present invention aims to prevent or treat NMD-related diseas...
|
|
WO/2022/175675A1 |
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, V, Z, U, X, Y and B are as define...
|
|
WO/2022/178438A1 |
Disclosed are POEGMA-aptamer conjugates with a reduced or eliminated host- immune response. An example conjugate includes an aptamer conjugated to a POEGMA having a plurality of side chains, where each side chain includes 1 to 6 monomers...
|
|
WO/2022/175666A1 |
The disclosure provides improved ADAMTS13 variants with amino acid substitutions in the linker 3 region. The disclosure also provides methods for producing and using the variants.
|
|
WO/2022/175509A1 |
Ovotransferrins with a degree of iron saturation from 0 to 15% are useful in the treatment of iron deficiency and iron deficiency anaemia, increasing the cell viability on gastric and intestinal cell models with respect to the holo-OvT 1...
|
|
WO/2022/177269A1 |
The present invention relates to a compound for inhibiting nonsense-mediated mRNA decay (hereinafter referred to as "NMD") or a pharmaceutically acceptably salt thereof. The present invention aims to prevent or treat an NMD-related disea...
|
|
WO/2022/171160A1 |
Benzazepine compounds, a preparation method therefor and pharmaceutical use thereof. Specifically, the present invention relates to a compound represented by formula II-1 or formula VIII-1, a pharmaceutical composition containing same, a...
|
|
WO/2022/170379A1 |
The present invention relates to a method of preparing a topical pharmaceutical composition, a pharmaceutical composition prepared by the method, a topical pharmaceutical composition, and to uses and methods involving the pharmaceutical ...
|
|
WO/2022/103966A9 |
Provided herein are methods of treating heart failure in patients exhibiting one or more additional features, comprising administering to the patient a therapeutically effective amount of omecamtiv mecarbil, or a hydrate, salt, or salt o...
|
|
WO/2022/171151A1 |
The present disclosure relates to an SMTP-7 derivative and the use thereof. In particular, provided is a compound as represented by formula I or a pharmaceutically acceptable salt thereof, wherein each group is as defined in the descript...
|
|
WO/2022/173818A1 |
Provided are methods for reducing the risk of drug-related hemolysis toxicity in subjects receiving primaquine and/or tafenoquine, for improving the therapeutic index of primaquine and/or tafenoquine in subjects, and for reducing the pro...
|
|
WO/2022/133061A9 |
Provided herein are cryopreservation compositions, e.g., infusion-ready cryopreservation compositions, pharmaceutical compositions comprising cryopreservation compositions, e.g., infusion-ready cryopreservation compositions, and methods ...
|
|
WO/2022/172006A1 |
The present invention relates to treatments of hereditary angioedema (HAE). In particular, the present invention provides on‐demand treatments of hereditary angioedema (HAE) by orally administering a plasma kallikrein inhibitor to a pa...
|
|
WO/2022/167778A1 |
Ebselen, 2-Phenyl-1,2-benzisoselenazol-3(2H)-one, (I) is a modulator of the adenosine A2A receptor and is indicated for use in the treatment or prevention of a disease or condition mediated by the adenosine A2A receptor.
|
|
WO/2022/169957A1 |
Photosynthetic compositions, methods of preparing photosynthetic compositions, and methods of using photosynthetic compositions are provided herein. Some photosynthetic compositions can be perfusable and comprise photosynthetic cells sus...
|
|
WO/2022/170200A1 |
The present invention refers to l-(2-sulfonyl-2,6-dihydropyrrolo[3,4- c]pyrazol-5(4H)-yl]-ethanone derivatives of formula (I) as pyruvate kinase (PKR) and/or PKM2 activators for use in the treatment of sickle cell disease, sickle cell an...
|
|
WO/2022/169946A1 |
The present disclosure provides methods and compositions for treating a condition associated with impaired lymphatic drainage.
|
|
WO/2022/169206A1 |
The present invention relates to a method for purification of hemopexin and haptoglobin and provides a method in which a solution containing hemopexin and haptoglobin is titrated to a range of specific pH values without a step of precipi...
|
